Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Xudong Zhang(Agricultural Genomics Institute at Shenzhen), Mingzhi Zhang(Chinese Academy of Sciences), Xiaofei Chai(First Affiliated Hospital of Zhengzhou University), Zunmin Zhu(Zhengzhou University), Rongjun Ma(Henan Provincial People's Hospital), Honghan Qiao(First Affiliated Hospital of Zhengzhou University), Xue Gao(Henan Cancer Hospital), Yufu Li(Henan Cancer Hospital)
Cited by 4
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
|Journal of Hematology & Oncology|2018|134